{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:57:04Z","timestamp":1791593824470,"version":"4.3.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T00:00:00Z","timestamp":1568246400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T00:00:00Z","timestamp":1568246400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroimmune Pharmacol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s11481-019-09871-0","type":"journal-article","created":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T13:02:54Z","timestamp":1568293374000},"page":"642-648","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Changes of Serum IgG Dimer Levels after Treatment with IVIg in Guillain-Barr\u00e9 Syndrome"],"prefix":"10.1007","volume":"14","author":[{"given":"Martin K. R.","family":"Sva\u010dina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"R\u00f6th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilja","family":"Bobylev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Sprenger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazim A.","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0674-9891","authenticated-orcid":false,"given":"Helmar C.","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,12]]},"reference":[{"issue":"Suppl","key":"9871_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/cei.1996.104.s1.10","volume":"104","author":"J Andersson","year":"1996","unstructured":"Andersson J, Skans\u00e9n-Saphir U, Sparrelid E, Andersson U (1996) Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes\/macrophages. Clin Exp Immunol 104(Suppl):10\u201320","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"9871_CR2","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1182\/blood.V95.5.1856.005k03_1856_1861","volume":"95","author":"WK Bleeker","year":"2000","unstructured":"Bleeker WK, Teeling JL, Verhoeven AJ, Rigter GM, Agterberg J, Tool AT, Hack CE (2000) Vasoactive side effects of intravenous immunoglobulin preparations in a rat model and their treatment with recombinant platelet-activating factor acetylhydrolase. Blood 95(5):1856\u20131861 Retrieved from http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10688848","journal-title":"Blood"},{"issue":"1","key":"9871_CR3","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.biologicals.2009.09.002","volume":"38","author":"R Bolli","year":"2010","unstructured":"Bolli R, Woodtli K, B\u00e4rtschi M, H\u00f6fferer L, Lerch P (2010) L-proline reduces IgG dimer content and enhances the stability of intravenous immunoglobulin (IVIG) solutions. Biologicals 38(1):150\u2013157. https:\/\/doi.org\/10.1016\/j.biologicals.2009.09.002","journal-title":"Biologicals"},{"issue":"1","key":"9871_CR4","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/acn3.687","volume":"6","author":"Maarten D. Brem","year":"2018","unstructured":"Brem MD, Jacobs BC, van Rijs W, Fokkink WJR, Tio-Gillen AP, Walgaard C et al (2019) IVIg-induced plasmablasts in patients with Guillain-Barr\u00e9 syndrome. Ann Clin Trans Neurol 6(1):129\u2013143. https:\/\/doi.org\/10.1002\/acn3.687","journal-title":"Annals of Clinical and Translational Neurology"},{"key":"9871_CR5","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1503\/cmaj.130375","volume":"187","author":"L Gilardin","year":"2015","unstructured":"Gilardin L, Bayry J, Kaveri SV (2015) Intravenous immunoglobulin as clinical immune-modulating therapy. CMAJ. 187:257\u2013264. https:\/\/doi.org\/10.1503\/cmaj.130375","journal-title":"CMAJ."},{"key":"9871_CR6","doi-asserted-by":"publisher","unstructured":"Hillion, S., Seit\u00e9, J.-F., Goutsmedt C., Yoinou, P., Pers, J.-O. (2013). Intravenous immunoglobulin induces functionnal silencing in human B lymphocytes. Ann. Rheum. Dis, 72, A37\u2013A38. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203219.20LK","DOI":"10.1136\/annrheumdis-2013-203219.20LK"},{"key":"9871_CR7","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/S0140-6736(78)92644-2","volume":"312","author":"RAC Hughes","year":"1978","unstructured":"Hughes RAC, Newsom-Davis JM, Perkin GD, Pierce JM (1978) Controlled trial of prednisolone in acute polyneuropathy. Lancet 312:750\u2013753. https:\/\/doi.org\/10.1016\/S0140-6736(78)92644-2","journal-title":"Lancet"},{"issue":"1","key":"9871_CR8","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/j.1365-2249.1990.tb05421.x","volume":"82","author":"T. W. JUNGI","year":"2008","unstructured":"Jungi TW, Brcic M, Kuhnert P, Spycher MO, Li F, Nydegger UE (1990) Effect of IgG for intravenous use on fc receptor-mediated phagocytosis by human monocytes. Clin Exp Immunol 82(1):163\u2013169.","journal-title":"Clinical & Experimental Immunology"},{"issue":"1\u20132","key":"9871_CR9","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jneuroim.2006.09.013","volume":"182","author":"K Kaida","year":"2007","unstructured":"Kaida K, Morita D, Kanzaki M, Kamakura K, Motoyoshi K, Hirakawa M, Kusunoki S (2007) Anti-ganglioside complex antibodies associated with severe disability in GBS. J Neuroimmunol 182(1\u20132):212\u2013218. https:\/\/doi.org\/10.1016\/j.jneuroim.2006.09.013","journal-title":"J Neuroimmunol"},{"issue":"21","key":"9871_CR10","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1212\/01.wnl.0000335160.72184.7d","volume":"71","author":"K Kaida","year":"2008","unstructured":"Kaida K, Sonoo M, Ogawa G, Kamakura K, Ueda-Sada M, Arita M, Kusunoki S (2008) GM1\/GalNAc-GD1a complex: a target for pure motor Guillain-Barr\u00e9 syndrome. Neurology 71(21):1683\u20131690. https:\/\/doi.org\/10.1212\/01.wnl.0000335160.72184.7d","journal-title":"Neurology"},{"key":"9871_CR11","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.autrev.2012.02.006","volume":"11","author":"SV Kaveri","year":"2012","unstructured":"Kaveri SV (2012) Intravenous immunoglobulin: exploiting the potential of natural antibodies. Autoimmun Rev 11:792\u2013794. https:\/\/doi.org\/10.1016\/j.autrev.2012.02.006","journal-title":"Autoimmun Rev"},{"issue":"1\u20132","key":"9871_CR12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jneuroim.2010.09.015","volume":"231","author":"HC Lehmann","year":"2011","unstructured":"Lehmann HC, Hartung H-P (2011) Plasma exchange and intravenous immunoglobulins: mechanism of action in immune-mediated neuropathies. J Neuroimmunol 231(1\u20132):61\u201369. https:\/\/doi.org\/10.1016\/j.jneuroim.2010.09.015","journal-title":"J Neuroimmunol"},{"issue":"1","key":"9871_CR13","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1046\/j.1471-4159.2000.0750404.x","volume":"75","author":"MPT Lunn","year":"2000","unstructured":"Lunn MPT, Johnson LA, Fromholt SE, Itonori S, Huang J, Vyas AA, Sheikh KA (2000) High-affinity anti-ganglioside IgG antibodies raised in complex ganglioside knockout mice: reexamination of GD1a immunolocalization. J Neurochem 75(1):404\u2013412. https:\/\/doi.org\/10.1046\/j.1471-4159.2000.0750404.x","journal-title":"J Neurochem"},{"issue":"148","key":"9871_CR14","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12974-015-0361-1","volume":"12","author":"C Ritter","year":"2015","unstructured":"Ritter C, Bobylev I, Lehmann HC (2015) Chronic inflammatory demyelinating polyneuropathy (CIDP): change of serum IgG dimer levels during treatment with intravenous immunoglobulins. J Neuroinflammation 12(148):148. https:\/\/doi.org\/10.1186\/s12974-015-0361-1","journal-title":"J Neuroinflammation"},{"issue":"4","key":"9871_CR15","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.4049\/jimmunol.144.4.1387","volume":"144","author":"KH Roux","year":"1990","unstructured":"Roux KH, Tankersley DL (1990) A view of the human idiotypic repertoire. Electron microscopic and immunologic analyses of spontaneous idiotype-anti-idiotype dimers in pooled human IgG. J Immunol 144(4):1387\u20131395 Retrieved from http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2303712","journal-title":"J Immunol"},{"issue":"4","key":"9871_CR16","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1182\/blood.V98.4.1095","volume":"98","author":"JL Teeling","year":"2001","unstructured":"Teeling JL, Jansen-Hendriks T, Kuijpers TW, De Haas M, Van De Winkel JGJ, Erik Hack C, Bleeker WK (2001) Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood 98(4):1095\u20131099. https:\/\/doi.org\/10.1182\/blood.V98.4.1095","journal-title":"Blood"},{"issue":"2","key":"9871_CR17","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/j.1537-2995.2012.03725.x","volume":"53","author":"T Tremblay","year":"2013","unstructured":"Tremblay T, Par\u00e9 I, Bazin R (2013) Immunoglobulin G dimers and immune complexes are dispensable for the therapeutic efficacy of intravenous immune globulin in murine immune thrombocytopenia. Transfusion 53(2):261\u2013269. https:\/\/doi.org\/10.1111\/j.1537-2995.2012.03725.x","journal-title":"Transfusion"},{"key":"9871_CR18","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S1474-4422(07)70130-8","volume":"6","author":"R van Koningsveld","year":"2007","unstructured":"van Koningsveld R, Steyerberg EW, Hughes RA, Swan AV, van Doorn PA, Jacobs BC (2007) A clinical prognostic scoring system for Guillain-Barr\u00e9 syndrome. Lancet Neurol 6:589\u2013594. https:\/\/doi.org\/10.1016\/S1474-4422(07)70130-8","journal-title":"Lancet Neurol"},{"issue":"Suppl 1","key":"9871_CR19","doi-asserted-by":"publisher","first-page":"S74","DOI":"10.1007\/s10875-010-9407-4","volume":"30","author":"PA van Doorn","year":"2010","unstructured":"van Doorn PA, Kuitwaard K, Walgaard C, van Koningsveld R, Ruts L, Jacobs BC (2010) IVIG treatment and prognosis in Guillain-Barre syndrome. J Clin Immunol 30(Suppl 1):S74\u2013S78. https:\/\/doi.org\/10.1007\/s10875-010-9407-4","journal-title":"J Clin Immunol"},{"issue":"Pt 5","key":"9871_CR20","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1093\/brain\/awh127","volume":"127","author":"G Zhang","year":"2004","unstructured":"Zhang G, Lopez PHH, Li CY, Mehta NR, Griffin JW, Schnaar RL, Sheikh KA (2004) Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies. Brain J. Neurol 127(Pt 5):1085\u20131100. https:\/\/doi.org\/10.1093\/brain\/awh127","journal-title":"Brain J. Neurol"}],"container-title":["Journal of Neuroimmune Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11481-019-09871-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11481-019-09871-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11481-019-09871-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T05:27:08Z","timestamp":1695187628000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11481-019-09871-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,12]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["9871"],"URL":"https:\/\/doi.org\/10.1007\/s11481-019-09871-0","relation":{},"ISSN":["1557-1890","1557-1904"],"issn-type":[{"value":"1557-1890","type":"print"},{"value":"1557-1904","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,12]]},"assertion":[{"value":"21 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For animal experiments, all applicable international, national, and\/or institutional guidelines for the care and use of animals were followed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Written informed consent was obtained from all subjects participating in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}